Abstract
Introduction: mRECIST were introduced in early 2000 for radiofrequency ablation (RFA) of lung tumours. This retrospective study was performed to evaluate mRECIST in the assessment of lung tumours t...
Highlights
MRECIST were introduced in early 2000 for radiofrequency ablation (RFA) of lung tumours
This study challenges the use of modified Response Evaluation Criteria in Solid Tumours (mRECIST) for the assessment of therapeutic response of lung tumours treated with microwave ablation (MWA) suggesting that timelines, especially regarding the baseline scan and ablation characteristics, may need to be revised
When the pre-ablation size was considered as baseline, the CT mass size increased to 219.7% of the original lesion on the 24-h post-ablation scan (Table 3)
Summary
MRECIST were introduced in early 2000 for radiofrequency ablation (RFA) of lung tumours. In the last few decades, minimally invasive percutaneous ablative techniques such as radiofrequency ablation (RFA) have been increasingly used as an alternative local therapy to treat both primary and metastatic lung malignancies in selected patients. By early 2000, its clinical application in treating lung tumours had been studied and accepted (Dupuy et al, 2000; Hiraki et al, 2007a, 2007b; Lencioni et al, 2008; Simon et al, 2007; Yamakado et al, 2007). After its introduction for the treatment of lung cancer, modified Response Evaluation Criteria in Solid Tumours (mRECIST) had been developed to assess the tumour response to RFA (Table 1). After its introduction for the treatment of lung cancer, modified Response Evaluation Criteria in Solid Tumours (mRECIST) had been developed to assess the tumour response to RFA (Table 1). (Herrera et al, 2003)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
